Daxor Corporation (DXR) 股票分析

公司概述

Daxor Corporation operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by developing specialized diagnostic equipment and biotechnology solutions. The company's core business involves the creation of the BVA-100 Blood Volume Analyzer, an instrument designed to measure human blood volume, which functions in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. In terms of scale, Daxor Corporation holds a market capitalization of $54.78M and reported trailing twelve-month revenue of $26,688, while the specific employee count is not publicly disclosed in available records. These financial metrics indicate that the company operates as a small-cap entity with minimal revenue relative to its equity value, suggesting a niche position in the medical technology landscape where valuation multiples often diverge significantly from traditional large-cap peers due to limited operational scale and specific product concentration.

财务健康

Daxor Corporation reported trailing twelve-month revenue of $26,688 alongside a net income of $9.17M, a discrepancy that reveals a highly distorted cost structure where reported expenses do not align with standard revenue generation models. The company generated free cash flow of $100,248, which theoretically suggests positive liquidity generation, yet this figure must be scrutinized against the context of its overall financial reporting anomalies. The company exhibits a gross margin of 100.0%, indicating no cost of goods sold relative to revenue, while simultaneously reporting an operating margin of -9660.6% and a profit margin of 34359.2%, figures that are statistically improbable for a standard manufacturing or service business and point to significant accounting irregularities or data reporting inconsistencies. Regarding liquidity and leverage, the available data lists total cash as N/A and total debt as $0, resulting in a debt-to-equity ratio of N/A, which technically implies a lack of recorded leverage but masks the reality of the cash position. The current ratio stands at 0.08, a figure that indicates severe short-term liquidity constraints, suggesting that current assets are less than one-fifth of current liabilities if the standard definition applies, or that the data reflects a structural imbalance in working capital management. Return on equity is recorded at 22.5%, while return on assets is -1.6%, metrics that reveal a divergence between equity efficiency and asset utilization, highlighting potential complexities in how management effectiveness is measured given the reported financial discrepancies.

估值评估

The trailing P/E ratio is listed at 5.73, whereas the forward P/E is N/A, implying that analysts cannot currently model future earnings growth due to the volatility or irregularity of the reported income statements. The price-to-book ratio is 1.04, which indicates that the market values the company at roughly equal to its book value, suggesting no significant premium or discount relative to net asset value despite the unusual financial profile. Alternative valuation metrics show a price-to-sales ratio of 2052.45 and an EV/EBITDA of N/A, figures that suggest extreme valuation multiples relative to revenue and indicate that traditional enterprise value comparisons are not applicable due to missing EBITDA data. The stock's trading range over the last year spans from a 52-week low of $7.10 to a 52-week high of $14.76, providing a reference band for price discovery within the volatile small-cap medical sector. The beta value is 0.14, which means the stock exhibits significantly lower price volatility relative to the broader market, moving less than one-fifth as much as the general market index during periods of fluctuation.

Growth & Income

Revenue growth year-over-year is reported at -82.6%, while earnings growth year-over-year is 329.3%, indicating a massive divergence where reported earnings are expanding at a rate vastly disproportionate to the decline in reported revenue. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically retained within the business rather than distributed to shareholders. Given the non-dividend paying status and the reinvestment of earnings into growth, the company relies on capital appreciation and operational scaling rather than income distributions to provide returns to its equity holders. The overall growth and income profile is characterized by extreme volatility in earnings metrics and a complete absence of dividend income, reflecting a high-risk, high-reward dynamic typical of early-stage or distressed medical technology firms attempting to stabilize their financial reporting.